Personalized Power: The End-to-End Path of Autologous T Cell Therapy
This autologous therapy not only offers a personalized solution to tumor heterogeneity and drug resistance but also holds promise for achieving longer-lasting remissions.
By closing in on the ALK oncogene—often the molecular Achilles’ heel of these cancers—we aim to shift the paradigm from transient inhibition to immune-mediated eradication.
The patient’s own immune system becomes the cornerstone of a custom-engineered cancer therapy.
01
T Cell Collection
T cells are collected from the patient’s blood through leukapheresis, marking the first step in the development of a personalized therapy.
T Cell Engineering
T cells are isolated and genetically modified via retroviral gene transfer to express a CAR or TCR capable of recognizing the ALK presented by tumor cells.
02
03
Expansion of Engineered T Cells
After genetic modification, the ALK-specific T cells are expanded in vitro to obtain a sufficient number of functional cells for therapeutic use.
Infusion into the Patient
The expanded ALK-specific T cells are infused back into the patient, marking the transition from laboratory to clinic.
04
From lab to life: engineered T cells re-enter the body to seek out ALK-positive cancer cells.
05
Target Recognition and Tumor Cell Elimination
Once in the body, the engineered T cells identify and kill ALK-positive cancer cells by recognizing their specific antigens.
